Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 11
in 84 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Alnylam Pharmaceuticals’ revenue topped consensus in the third fiscal quarter of 2026, reported October 29, 2026, with revenue up 16.7% year over year to about $1.5 billion (up from roughly $1.2 billion a year ago) and coming in at $1.458 billion versus the $1.431 billion estimate (+1.9%, topped). Profitability tracked a high-margin mix, with gross profit of about $1.1 billion translating to a gross margin of roughly 75%, while operating income of roughly $345.8 million put operating margin near 24%. The quarter generated operating cash flow of about $341.0 million. For the next period, consensus calls for EPS of $2.83 on revenue of $1.547 billion.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. develops RNA interference medicines in biotechnology and markets treatments for rare diseases, with $3.7 billion in revenue in FY2025. Listed on NASDAQ as ALNY, the company sells ONPATTRO for polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1.
Today's Snapshot
The day ended with ALNY 4.5% lower at 149.40, in line with a weaker sector. At the close, ALNY was within 1.2% of its 52-week low of 147.58. TradingView analysts, a market-data service, cut Alnylam’s 12-month price target to $279.
Trading Volume
Below 10d avg (2.9M)
2.5M
vs S&P 500 Today
Strong Underperformance
-4.28%
Updated: November 18, 2026 at 21:16 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$160.48 - $276.19Sell
- RSI (14)28.51Buy
- Stochastic %K (14, 3, 3)10.63Buy
- MACD Level (12, 26)-18.39Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.